Apogee Therapeutics Inc. Overview

Apogee Therapeutics, Inc., a biotech company headquartered in Waltham, United States, is making strides in the healthcare sector with its focus on developing differentiated antibody therapeutics. The company targets the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD), and other inflammatory and immune diseases that have significant unmet medical needs.

Financial Snapshot

As of May 8, 2025, Apogee Therapeutics’ stock closed at $37.29 on the Nasdaq exchange. The company’s market capitalization stands at approximately $1.58 billion USD. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $63.50 on November 10, 2024, and a 52-week low of $26.20 on April 7, 2025.

Strategic Focus

Apogee Therapeutics is dedicated to addressing high unmet needs in the treatment of inflammatory and immune diseases. By focusing on innovative antibody therapeutics, the company aims to provide new solutions for conditions such as atopic dermatitis and COPD, which affect millions of patients worldwide.

Conclusion

With its strategic focus on differentiated antibody therapeutics and a robust pipeline targeting significant unmet medical needs, Apogee Therapeutics, Inc. continues to position itself as a key player in the biotech industry. Investors and stakeholders will be closely monitoring the company’s progress in bringing new treatments to market.